All In Biotech

Drug Trial Radar · NCT06576271

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

A Phase 1, First-time-in-human, Four-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

143

Actual

Start

Sep 2, 2024

Primary completion

Feb 1, 2028

Study completion Feb 1, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • GSK4527363Drug

    GSK4527363 will be administered to participants.

  • Placebo matching GSK4527363Drug

    Placebo matching GSK4527363 will be administered to participants.

  • BelimumabDrug

    Belimumab will be administered to participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and C: Number of Participants with Non-serious Adverse Events and Serious Adverse EventsTime frame: Up to Week 52
  2. Parts B and D: Number of Participants with Non-serious Adverse Events and Serious Adverse EventsTime frame: Up to Week 68
  3. Parts A and C: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) FindingsTime frame: Up to Week 52
  4. Parts B and D: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) FindingsTime frame: Up to Week 68
  5. Parts A and C: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 52
  6. Parts B, and D: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 68

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    San Juan Bautista, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina

  • GSK Investigational Site

    Juiz de Fora, Brazil

  • GSK Investigational Site

    Porto Alegre, Brazil

  • GSK Investigational Site

    Salvador, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Bydgoszcz, Poland

  • GSK Investigational Site

    Poznan, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Wroclaw, Poland

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Bilbao, Spain

  • GSK Investigational Site

    Sabadell Barcelona, Spain

  • GSK Investigational Site

    Valladolid, Spain

  • GSK Investigational Site

    Pamplona Iruna, Navarre, Spain

  • GSK Investigational Site

    Cambridge, United Kingdom

  • GSK Investigational Site

    Liverpool, United Kingdom

  • GSK Investigational Site

    London, United Kingdom

  • GSK Investigational Site

    Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.